<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/1320e" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/1320e/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/1320e/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_1320e"><akn:num>1320e</akn:num><akn:heading>Comparative clinical effectiveness research</akn:heading><akn:content><akn:p>§ 1320e. Comparative clinical effectiveness research(a) DefinitionsIn this section:(1) BoardThe term “Board” means the Board of Governors established under subsection (f).


(2) Comparative clinical effectiveness research; research(A) In generalThe terms “comparative clinical effectiveness research” and “research” mean research evaluating and comparing health outcomes and the clinical effectiveness, risks, and benefits of 2 or more medical treatments, services, and items described in subparagraph (B).


(B) Medical treatments, services, and items describedThe medical treatments, services, and items described in this subparagraph are health care interventions, protocols for treatment, care management, and delivery, procedures, medical devices, diagnostic tools, pharmaceuticals (including drugs and biologicals), integrative health practices, and any other strategies or items being used in the treatment, management, and diagnosis of, or prevention of illness or injury in, individuals.



(3) Conflict of interestThe term “conflict of interest” means an association, including a financial or personal association, that have 11 So in original. Probably should be “has”. the potential to bias or have 1 the appearance of biasing an individual’s decisions in matters related to the Institute or the conduct of activities under this section.


(4) Real conflict of interestThe term “real conflict of interest” means any instance where a member of the Board, the methodology committee established under subsection (d)(6), or an advisory panel appointed under subsection (d)(4), or a close relative of such member, has received or could receive either of the following:(A) A direct financial benefit of any amount deriving from the result or findings of a study conducted under this section.

(B) A financial benefit from individuals or companies that own or manufacture medical treatments, services, or items to be studied under this section that in the aggregate exceeds $10,000 per year. For </akn:p></akn:content><akn:subsection eId="subsec_1320e_a"><akn:num>(a)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(a) Definitions In this section:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320e_b"><akn:num>(b)</akn:num><akn:heading>Patient-Centered Outcomes Research Institute</akn:heading><akn:content><akn:p>(b) Patient-Centered Outcomes Research Institute</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320e_c"><akn:num>(c)</akn:num><akn:heading>Purpose</akn:heading><akn:content><akn:p>(c) Purpose The purpose of the Institute is to assist patients, clinicians, purchasers, and policy-makers in making informed health decisions by advancing the quality and relevance of evidence concerning the manner in which diseases, disorders, and other health conditions can effectively and appropriately be prevented, diagnosed, treated, monitored, and managed through research and evidence synthesis that considers variations in patient subpopulations, and the dissemination of research findings with respect to the relative health outcomes, clinical effectiveness, and appropriateness of the medical treatments, services, and items described in subsection (a)(2)(B).</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320e_d"><akn:num>(d)</akn:num><akn:heading>Duties</akn:heading><akn:content><akn:p>(d) Duties</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320e_e"><akn:num>(e)</akn:num><akn:heading>Administration</akn:heading><akn:content><akn:p>(e) Administration</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320e_f"><akn:num>(f)</akn:num><akn:heading>Board of Governors</akn:heading><akn:content><akn:p>(f) Board of Governors</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320e_g"><akn:num>(g)</akn:num><akn:heading>Financial and governmental oversight</akn:heading><akn:content><akn:p>(g) Financial and governmental oversight</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320e_h"><akn:num>(h)</akn:num><akn:heading>Ensuring transparency, credibility, and access</akn:heading><akn:content><akn:p>(h) Ensuring transparency, credibility, and access The Institute shall establish procedures to ensure that the following requirements for ensuring transparency, credibility, and access are met:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320e_i"><akn:num>(i)</akn:num><akn:heading>Rules</akn:heading><akn:content><akn:p>(i) Rules The Institute,5 its Board or staff, shall be prohibited from accepting gifts, bequeaths,77 So in original. Probably should be “bequests”. or donations of services or property. In addition, the Institute shall be prohibited from establishing a corporation or generating revenues from activities other than as provided under this section.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320e_j"><akn:num>(j)</akn:num><akn:heading>Rules of construction</akn:heading><akn:content><akn:p>(j) Rules of construction</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>